|
BACKGROUND: Deep vein thrombosis (lower deep venous thrombosis, LDVT) is a common peripheral vascular disease, the incidence rate of about 40% of peripheral vascular disease. Nearly 20 years LDVT an upward trend, and sequelae of LDVT approximately 30 million patients and has become a common threat to people's health, in the acute phase stage if not timely diagnosis and treatment, some patients may be caused due to thrombosis embolism (pulmonary embolism , PE), a serious threat to the lives of patients. Reported in the literature in the United States die each year from PE by about 10 million people, while many people can not survive in the deep vein thrombosis sequelae (post-thrombosis syndrome, PTS) occurrence, resulting in chronic pain, affecting people's work and life. Thus, in clinical studies of DVT in the early diagnosis and timely treatment and therapeutic evaluation has very important significance. Objective: To investigate LDVT plasma of patients with platelet surface P-selectin (CD62P), lysosomal granules glycoprotein (CD63) and D-dimer (DD) in thrombolysis, anticoagulation, antiplatelet other variation before and after treatment . Subjects and Methods: First Affiliated Hospital of Anhui Medical University, Vascular Surgery, 31 cases of hospitalized patients diagnosed as LDVT case group, 28 cases of non-vascular related diseases outpatient minor surgery patients as the control group. Admission, blood samples were collected first, after thrombolysis, anticoagulant, anti-platelet therapy after a second blood samples collected 72h, 7d of treatment blood samples were collected after the third time. To the median cubital vein blood, blood volume of about three 2ml, sodium citrate (Natrium citricum) anticoagulation, the use of flow cytometry (Flow cytometry, FCM) plasma CD62P, CD63 positive expression rate, while applying Immunoturbidimetry France (LIATEST) plasma DD levels, the indicators before and after treatment changes, and further analysis of its circumference and lower limbs with poor correlation. Results: 1.LDVT patients before CD62P, CD63 expression was higher than the normal control group (P lt; 0.01); After thrombolysis, anticoagulation, antiplatelet therapy after 3d, CD62P positive expression rate of decline, but CD62P and treatment There was no prior significant difference (P gt; 0.05), CD63 was significantly decreased compared with before treatment, there were significant differences (P lt; 0.01); treatment after 7d CD62P, CD63 expression compared with before treatment were significantly decline, with a significant difference (P lt; 0.01), CD62P, CD63 expression was still higher. 2.LDVT DD patients before treatment was higher than the normal control group, with significant difference (P lt; 0.01); treatment 3d DD tended to increase, compared with before treatment there was significant difference (P lt; 0.01); DD 7d after treatment decreased to near pre-treatment levels, compared with before treatment had no significant difference (P gt; 0.05), but the content is still higher than DD. 3 In the course of treatment, lower extremity circumference difference downward trend. Pre-treatment and treatment of limb circumference difference after 3d, 7d differences were statistically significant (P lt; 0.01), and the treatment and treatment of 3d 7d significant difference compared (P lt; 0.01) 4.CD62P, CD63 changes trends and changes in lower extremity circumference difference is consistent. Conclusions: 1. Plasma CD62P, CD63, DD and LDVT closely related. 2.CD62P, CD63, DD LDVT are involved in the formation process, and in the course of treatment showed dynamic changes, can be used as an important indicator of LDVT early diagnosis and evaluation of the efficacy of effective indicators, but also for patients LDVT provide a new way, and based on these indicators for drug doses used to provide reference. 3.LDVT patients after 7d, CD62P, CD63, and DD is still higher than the normal control group, after discharge is still at high risk of thrombosis, the need for regular follow-up.
|